Publication date: Oct 12, 2024
Denovos discovery of a novel pharmacogenomic biomarker, DGM4, presents a new era for liafensine, a first-in-class triple reuptake inhibitor. Over 30% patients with MDD do not benefit from currently available antidepressants and are diagnosed with treatment-resistant depression (TRD). Furthermore, clinicians have challenges identifying the appropriate therapies that most likely benefit these patients.
| Concepts | Keywords |
|---|---|
| Dgm4 | Biomarker |
| Fast | Denovo |
| Fda | Depression |
| Phd | Designation |
| Schizophrenia | Drug |
| Drugs | |
| Fast | |
| Fda | |
| Liafensine | |
| Liafensines | |
| Precision | |
| Resistant | |
| Track | |
| Trd | |
| Treatment |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Dopamine |
| disease | MESH | schizophrenia |
| drug | DRUGBANK | Norepinephrine |
| drug | DRUGBANK | Serotonin |
| disease | MESH | major depressive disorder |
| disease | MESH | weight gain |
| disease | MESH | movement disorders |
| disease | MESH | respiratory depression |
| disease | MESH | dissociation |
| disease | MESH | psychiatric diseases |
| drug | DRUGBANK | Methionine |
| disease | MESH | depression |
Original Article
(Visited 3 times, 1 visits today)